Advertisement

Diabetes, Obesity, and the Metabolic Syndrome

  • Robert M. Kaplan
Chapter

Diabetes mellitus (DM) or diabetes, as we usually call it, is a major medical, personal, and public-health problem. Diabetes is a chronic disease associated with abnormally high levels of glucose (sugars) in the blood. A rise in glucose occurs when foods are consumed. Glucose from blood is an energy source for cells and tissues throughout the body. However, utilization of glucose requires a hormone, insulin, that allows the glucose to be used. Diabetes occurs when the body does not make enough insulin or when cells cannot adequately make use of the available insulin. In 2006, the American Diabetes Association (ADA) estimated that 20.8 million people, roughly 7 percent of the US population, had diabetes. Among these, 14.6 million have been diagnosed, and 6.2 million are unaware they have the condition. Another 41 million have “pre-diabetes,”[1] a condition many experts believe leads to diabetes.

The incidence of the disease in the US population varies with age. For those over 60, more...

Keywords

Metabolic Syndrome Oral Glucose Tolerance Test Lifestyle Intervention American Diabetes Association Impaired Fasting Glucose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Association AD. Diabetes 4-1-1: Facts, Figures, and Statistics at a Glance. Atlanta: American Diabetes Association; 2006.Google Scholar
  2. 2.
    Health, United States, 2005. Atlanta: Centers for Disease Control and Prevention; 2005.Google Scholar
  3. 3.
    Herman WH, Sinnock P, Brenner E, et al. An epidemiologic model for diabetes mellitus: incidence, prevalence, and mortality. Diabetes Care. Jul–Aug 1984;7(4):367–371.CrossRefGoogle Scholar
  4. 4.
    Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. Feb 7 2002;346(6): 393–403.CrossRefGoogle Scholar
  5. 5.
    Harris EL, Wagener DK, Dorman JS, Drash AL. Detection of genetic heterogeneity between families of insulin-dependent diabetes mellitus patients using linkage analysis. Am J Hum Genet. Jan 1985;37(1):102–113.Google Scholar
  6. 6.
    Polonsky KS. Dynamics of insulin secretion in obesity and diabetes. Int J Obes Relat Metab Disord. Jun 2000;24(Suppl 2):S29–S31.Google Scholar
  7. 7.
    de Luca C, Olefsky JM. Stressed out about obesity and insulin resistance. Nat Med. Jan 2006;12(1):41–42; discussion 42.CrossRefGoogle Scholar
  8. 8.
    Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. Aug 2000; 106(3):329–333.CrossRefGoogle Scholar
  9. 9.
    Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. Jul 1997;20(7):1183–1197.Google Scholar
  10. 10.
    Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. Nov 2003;26(11):3160–3167.CrossRefGoogle Scholar
  11. 11.
    Hanefeld M, Temelkova-Kurktschiev T, Schaper F, Henkel E, Siegert G, Koehler C. Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med. Mar 1999;16(3):212–218.CrossRefGoogle Scholar
  12. 12.
    Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. Feb 12 2001;161(3):397–405.CrossRefGoogle Scholar
  13. 13.
    Shaw JE, Zimmet PZ, Hodge AM, et al. Impaired fasting glucose: how low should it go? Diabetes Care. Jan 2000;23(1):34–39.CrossRefGoogle Scholar
  14. 14.
    Gabir MM, Hanson RL, Dabelea D, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care. Aug 2000;23(8):1108–1112.CrossRefGoogle Scholar
  15. 15.
    Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, et al. Prevalence of hypertension in Hispanic and non-Hispanic white populations. Hypertension. Feb 2002;39(2):203–208.CrossRefGoogle Scholar
  16. 16.
    Kaplan RM, Morton D, Wingard DL, Barrett-Connor E. Should the threshold for fasting plasma glucose be reduced: The Rancho Bernardo Study. Unpublished manuscript. 2006.Google Scholar
  17. 17.
    Kanaya AM, Herrington D, Vittinghoff E, et al. Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. Ann Intern Med. May 17 2005;142(10):813–820.Google Scholar
  18. 18.
    Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. Sep 2002;51(9):2796–2803.CrossRefGoogle Scholar
  19. 19.
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. Jun 15 2002;359(9323):2072–2077.CrossRefGoogle Scholar
  20. 20.
    Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. Apr 1997;20(4):537–544.CrossRefGoogle Scholar
  21. 21.
    Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. May 3 2001;344(18):1343–1350.CrossRefGoogle Scholar
  22. 22.
    Kaplan RM, Ganiats TG, Sieber WJ, Anderson JP. The Quality of Well-Being Scale: critical similarities and differences with SF-36 [see comments]. Int J Qual Health C. 1998;10(6):509–520.CrossRefGoogle Scholar
  23. 23.
    Kaplan RM, Ganiats TG. Qalys – their ethical implications. JAMA. 1990;264(19): 2502–2503.CrossRefGoogle Scholar
  24. 24.
    Groessl EJ, Kaplan RM, Barrett-Connor E, Ganiats TG. Body mass index and quality of well-being in a community of older adults. Am J Prev Med. Feb 2004;26(2):126–129.CrossRefGoogle Scholar
  25. 25.
    Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying? Health Aff (Millwood). Jan–Jun 2003;Suppl Web Exclusives:W3-219-226.Google Scholar
  26. 26.
    Finkelstein EA, Ruhm CJ, Kosa KM. Economic causes and consequences of obesity. Annu Rev Public Health. 2005;26:239–257.CrossRefGoogle Scholar
  27. 27.
    Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. JAMA. Oct 27 1999;282(16):1530–1538.CrossRefGoogle Scholar
  28. 28.
    Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. Aug 24 2006;355(8): 763–778.CrossRefGoogle Scholar
  29. 29.
    Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. Jan 2006;21(1):1–6.CrossRefGoogle Scholar
  30. 30.
    Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. Nov 2005;28(11):2745–2749.CrossRefGoogle Scholar
  31. 31.
    Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. Sep 2005;28(9):2289–2304.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Robert M. Kaplan
    • 1
  1. 1.UCLA School of Public HealthLos AngelesUSA

Personalised recommendations